Latest Period
Q1 2026
Security Snapshot
IOVANCE BIOTHERAPEUTICS, INC. - COMMON STOCK (IOVA) Institutional Ownership
CUSIP: 462260100
13F Institutional Holders and Ownership History from Q2 2017 to Q1 2026
Institutions Reporting
281
Shares (Excl. Options)
268,989,170
Price
$3.51
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- IOVA on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 268,989,170
- Total 13F value
- $943,337,968
- Portfolio coverage rank
- 0%
- Share change
- +3,509,502
- Value change
- +$17,193,424
- Number of holders
- 281
- Shares outstanding
- 415,431,143
- SEC-reported price per share
- $3.62
- Insider filing price
- $3.62
Latest holder snapshot
5 signals
Issuer context
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- IOVA - IOVANCE BIOTHERAPEUTICS, INC. - COMMON STOCK is tracked under CUSIP 462260100.
- 281 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 260 to 281 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $713,891,876 to $943,337,968.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 281 institutions filings for Q1 2026.
Security key
462260100
Latest holder period
Q1 2026
13F holders
281
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
IOVA full holder history
IOVANCE BIOTHERAPEUTICS, INC. SEC filings
IOVANCE BIOTHERAPEUTICS, INC. company facts
IOVANCE BIOTHERAPEUTICS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 462260100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
IOVA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 6.4% | $36,645,720 | 21,305,651 | BlackRock, Inc. | 30 Jun 2025 | |||
| STATE STREET CORP | 4.2% | -18% | $69,966,913 | -$10,880,481 | 17,448,108 | -13% | STATE STREET CORPORATION | 31 Mar 2026 |
| PERCEPTIVE ADVISORS LLC | 3.8% | -50% | $45,599,285 | -$33,120,382 | 12,808,788 | -42% | Perceptive Advisors LLC | 31 Mar 2025 |
As of 31 Mar 2026, 281 institutional investors reported holding 268,989,170 shares of IOVANCE BIOTHERAPEUTICS, INC. - COMMON STOCK (IOVA). This represents 65% of the company’s total 415,431,143 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
52%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7.5% | 31,080,505 | +5.3% | 0% | $109,092,571 |
| MHR FUND MANAGEMENT LLC | 7% | 28,967,103 | 0% | 7.4% | $101,674,532 |
| STATE STREET CORP | 4.2% | 17,448,108 | -13% | 0% | $61,242,859 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4% | 16,617,737 | 0% | 0% | $58,328,257 |
| TWO SIGMA INVESTMENTS, LP | 3.3% | 13,687,433 | +211% | 0.04% | $48,042,890 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.8% | 11,700,844 | 0% | 0% | $41,069,962 |
| MILLENNIUM MANAGEMENT LLC | 2.3% | 9,414,292 | +43% | 0.02% | $33,044,165 |
| GOLDMAN SACHS GROUP INC | 2.1% | 8,760,060 | +1.8% | 0% | $30,747,811 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 8,572,598 | +7.3% | 0% | $30,095,090 |
| Invenomic Capital Management LP | 2% | 8,495,551 | -29% | 1.4% | $29,819,384 |
| BANK OF AMERICA CORP /DE/ | 2% | 8,490,119 | -41% | 0% | $29,800,318 |
| D. E. Shaw & Co., Inc. | 1.9% | 8,016,353 | +109% | 0.02% | $28,137,399 |
| Palo Alto Investors LP | 1.5% | 6,349,563 | -11% | 3.4% | $22,286,966 |
| MORGAN STANLEY | 1.5% | 6,201,282 | -33% | 0% | $21,766,499 |
| JANE STREET GROUP, LLC | 1% | 4,173,886 | +16% | 0.02% | $14,650,340 |
| Nuveen, LLC | 0.88% | 3,664,278 | +164% | 0% | $12,861,616 |
| HRT FINANCIAL LP | 0.84% | 3,486,299 | -20% | 0.03% | $12,236,000 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.76% | 3,166,861 | +166% | 0% | $11,116,000 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.72% | 2,996,743 | -39% | 0.01% | $10,518,568 |
| NORTHERN TRUST CORP | 0.69% | 2,875,526 | +11% | 0% | $10,093,096 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.67% | 2,783,730 | +1.1% | 0% | $9,770,892 |
| DIMENSIONAL FUND ADVISORS LP | 0.64% | 2,645,702 | +72% | 0% | $9,281,902 |
| CITADEL ADVISORS LLC | 0.63% | 2,611,345 | -17% | 0.01% | $9,165,821 |
| JPMORGAN CHASE & CO | 0.6% | 2,500,624 | -17% | 0% | $8,302,072 |
| MARSHALL WACE, LLP | 0.57% | 2,355,612 | 0.01% | $8,268,198 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
36
Latest
Q1 2026
Rows shown
1-25 of 36
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 268,989,170 | $943,337,968 | +$17,193,424 | $3.51 | 281 |
| 2025 Q4 | 261,538,056 | $713,891,876 | +$134,068,597 | $2.73 | 260 |
| 2025 Q3 | 213,023,331 | $462,262,436 | -$12,426,646 | $2.17 | 249 |
| 2025 Q2 | 220,039,758 | $378,480,610 | -$103,966,458 | $1.72 | 244 |
| 2025 Q1 | 239,455,648 | $797,796,916 | -$41,501,290 | $3.33 | 292 |
| 2024 Q4 | 241,507,506 | $1,786,983,312 | +$22,988,107 | $7.40 | 294 |
| 2024 Q3 | 235,201,336 | $2,210,596,727 | +$25,452,589 | $9.39 | 280 |
| 2024 Q2 | 232,474,427 | $1,864,558,933 | +$97,335,567 | $8.02 | 287 |
| 2024 Q1 | 217,101,064 | $3,216,301,753 | +$212,421,390 | $14.82 | 266 |
| 2023 Q4 | 207,297,037 | $1,685,397,432 | -$32,505,370 | $8.13 | 233 |
| 2023 Q3 | 213,137,480 | $969,776,344 | +$6,686,675 | $4.55 | 223 |
| 2023 Q2 | 203,959,385 | $1,435,734,710 | -$789,310 | $7.04 | 214 |
| 2023 Q1 | 205,425,383 | $1,254,751,936 | +$199,378,894 | $6.11 | 225 |
| 2022 Q4 | 173,249,347 | $1,106,975,435 | +$100,178,837 | $6.39 | 213 |
| 2022 Q3 | 154,414,415 | $1,478,691,442 | -$53,630,372 | $9.58 | 231 |
| 2022 Q2 | 156,417,705 | $1,726,071,008 | +$13,073,879 | $11.04 | 227 |
| 2022 Q1 | 155,843,237 | $2,593,671,140 | -$16,926,612 | $16.65 | 231 |
| 2021 Q4 | 155,850,778 | $2,963,320,040 | -$77,138,233 | $19.09 | 235 |
| 2021 Q3 | 157,966,360 | $3,882,977,675 | -$126,474,780 | $24.66 | 238 |
| 2021 Q2 | 162,111,422 | $4,215,394,735 | +$75,696,267 | $26.02 | 226 |
| 2021 Q1 | 156,513,608 | $4,954,837,773 | +$228,194,179 | $31.66 | 240 |
| 2020 Q4 | 148,752,147 | $6,902,468,525 | +$436,980,892 | $46.40 | 264 |
| 2020 Q3 | 139,955,271 | $4,606,819,956 | -$20,115,200 | $32.92 | 245 |
| 2020 Q2 | 140,811,545 | $3,876,458,222 | +$501,586,010 | $27.45 | 254 |
| 2020 Q1 | 122,545,305 | $3,667,866,974 | -$30,050,711 | $29.94 | 214 |